×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript May 7, 2024 Aclaris Therapeutics, Inc. beats earnings expectations...
2 weeks ago
Stifel Maintains Aclaris Therapeutics (ACRS) Buy Recommendation
MSN
Fintel reports that on September 14, 2023, Stifel maintained coverage of Aclaris Therapeutics (NASDAQ:ACRS) with a Buy recommendation.
4 days ago
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Fierce Biotech
Aclaris lays off 46% of staff, resurrects zunsemetinib as potential cancer treatment ... Aclaris Therapeutics has decided to give its MK2...
5 months ago
Aclaris Therapeutics First Quarter 2024 Earnings: Beats Expectations
Simply Wall Street
Aclaris Therapeutics ( NASDAQ:ACRS ) First Quarter 2024 Results Key Financial Results Revenue: US$2.40m (down 5.1% from...
1 week ago
Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial
BioSpace
Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II...
6 months ago
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Aclaris (ACRS) delivered earnings and revenue surprises of 14.29% and 20.62%, respectively, for the quarter ended March 2024.
2 weeks ago
Aclaris' stocks plummet after zunsemetinib discontinuation
Clinical Trials Arena
Aclaris Therapeutics announced it is also discontinuing a Phase IIa trial of zunsemetinib in psoriatic arthritis.
6 months ago
Aclaris: Q1 Earnings Snapshot
Milford Mirror
WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $16.9 million in its first quarter.
2 weeks ago
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
GlobeNewswire
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
3 weeks ago
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Yahoo Finance
Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE...
2 weeks ago